| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9af4862fb709235a3ffd4e65934db71d |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-14 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-1138
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-713
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-713
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-02 |
| filingDate |
2006-10-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2011-01-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ef8404c4f6e51e4437df11e6b4609abc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_93375ef7b29afb4b88237360a7c9478a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d0c4cdf8bb57b5d967dfb5a47de33822
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_85c00fe958d649c6ac73dc8b579498fb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b7b4743e279d4d7bcea6c2841901680a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1e7d7759d1500cddc8ae22f3ca7e1c5c |
| publicationDate |
2011-01-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-1937281-B1 |
| titleOfInvention |
Modulation of trpv expression levels |
| abstract |
The present invention relates to methods and compositions for the treatment and/or the prevention of conditions related to high levels of expression and/ or activity of the transient receptor potential vanilloid-1 (TRPV1). Amongst others, the conditions to be treated are eye conditions such as discomfort and altered sensitivity of the cornea following refractive surgery, use of contact lenses, dry eyes and diabetic retinopathy. |
| priorityDate |
2005-10-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |